CJC-1295 Buyer's Guide: 4 Decisions Before You Buy

Your pituitary doesn't release growth hormone in a steady stream. It releases it in sharp, concentrated bursts, and those bursts are what make the whole system work. Understanding why that matters is the only way to understand what you're actually buying when you buy CJC-1295.

The chain works like this. Your hypothalamus releases something called growth hormone releasing hormone, or GHRH, which is the signal that tells your pituitary to fire. The pituitary responds by releasing a pulse of growth hormone into your bloodstream. That growth hormone then travels to your liver, where it stimulates the production of something called IGF-1, which is insulin-like growth factor 1, and IGF-1 is the molecule that actually drives most of the downstream effects you're after, things like muscle protein synthesis, fat metabolism, and tissue repair. That's the full chain: hypothalamus fires, pituitary pulses, liver converts, body responds.

CJC-1295 without DAC is a synthetic version of GHRH. It binds to the same receptors your pituitary uses to detect the natural GHRH signal, and it triggers the same downstream pulse. The half-life of natural GHRH is only a few minutes in circulation, and CJC without DAC extends that to somewhere around 30 minutes, which is long enough to generate a meaningful pulse before the signal fades. That's the design. Short burst, pituitary fires, system responds normally.

CJC-1295 with DAC changes that entirely.

DAC stands for drug affinity complex, and what it does is bind the peptide to albumin, which is a carrier protein that already exists in your blood and is responsible for transporting various compounds throughout your body. When CJC binds to albumin, it stops being cleared. The half-life extends from about 30 minutes to roughly 7 days, which means instead of a pulse, you now have a continuous low-level elevation of GHRH signal circulating all week.

Here's why that's a problem. Your pituitary is built to respond to sharp peaks, not flat baselines. The same mechanism that makes pulses effective is the reason continuous stimulation stops working. When your pituitary is chronically bathed in GHRH signal without the natural off-periods, it down-regulates its response, meaning the system that was designed to fire in response to contrast becomes desensitized to constant noise. If what you want is a flat elevation of growth hormone, exogenous growth hormone already does that, and it has decades of clinical data behind it. The only version of CJC-1295 worth buying is the one without DAC.

Now, most people pair CJC-1295 with Ipamorelin, and that combination is where the practical decisions start multiplying.

Ipamorelin works through a completely different receptor called GHSR1a, which is the ghrelin receptor. Where CJC is hitting the GHRH pathway and telling the pituitary to release growth hormone, Ipamorelin is hitting the ghrelin pathway and amplifying the amplitude of that release. The two signals converge at the pituitary and produce a larger, more defined pulse than either would generate alone. That's why the combination became the standard protocol.

When you buy these compounds together in a premixed blend, the math matters. Five milligrams of CJC and five milligrams of Ipamorelin in two milliliters of bacteriostatic water gives you a concentration where every 10 units drawn on an insulin syringe contains 250 micrograms of each peptide. Getting that conversion right before you start is how you avoid either underdosing or running out of one compound before the other.

The question people ask about cycling is why it's necessary at all, and the answer points entirely to the Ipamorelin side of the protocol.

GHRH receptors, the ones CJC is working through, do not appear to desensitize under continuous stimulation in any clinically meaningful way. The clearest evidence for this is tesamorelin, which is an FDA-approved GHRH analog used in HIV-associated lipodystrophy. In the 52-week clinical trial that supported FDA approval, subjects dosed tesamorelin continuously for a full year and IGF-1 levels held steady through week 52 at the same levels seen at week 26. No decline. The GHRH pathway, when stimulated appropriately, keeps responding.

The ghrelin receptor is a different story. Something called beta-arrestin-mediated desensitization occurs at GHSR1a, which is a mechanism where the receptor essentially pulls itself away from the cell surface in response to prolonged stimulation, reducing the number of available receptors and therefore the magnitude of the response. This is not unique to Ipamorelin. It's a property of the receptor class itself. After 12 to 16 weeks of continuous use, IGF-1 levels can drop 20 to 30 percent from the peak you saw during the first weeks of the protocol, even at the same dose. The signal is still going in. The receptor has just stopped listening as loudly.

That's the entire reason for the three-months-on, one-month-off cycle. The month off allows GHSR1a receptor density to recover, which means when you restart, you're back to the same baseline sensitivity you had at week one. The CJC doesn't need the break. The Ipamorelin does.

The last decision is knowing when secretagogues stop being the right tool.

Secretagogues work within your biological ceiling. They optimize what your hypothalamic-pituitary axis can produce on its own, and because the pituitary is doing the releasing, the normal feedback loops stay intact. Your body can still regulate things like somatostatin release, which is the braking signal that keeps growth hormone from running too high. The system retains its checks.

Exogenous growth hormone bypasses the ceiling entirely because you're injecting the hormone directly and the pituitary is no longer the rate-limiting step. But here's what makes running both at the same time counterproductive. After a single injection of exogenous growth hormone, somatostatin inhibits the GHRH pathway by 86 percent. That's not a minor blunting effect. That's a near-complete shutdown of the receptor pathway that CJC-1295 depends on to function. You're paying for a peptide that physiologically cannot do its job when growth hormone is already elevated through exogenous injection.

So the decision tree is actually simple. If your goals are within what your body can produce on its own, secretagogues with an intact feedback loop are the right tool. If your goals require going past that ceiling, you switch to exogenous growth hormone and drop the secretagogues entirely. Trying to run both is just paying for two things while getting the benefit of one.

The deeper point is that most of the mistakes people make with these compounds come from treating the protocol as a list of doses rather than a system with internal logic. The DAC question, the cycling question, the transition question, they all have the same answer underneath them: understand what the receptor is doing, and the right decision becomes obvious.

---

References

1. FDA Prescribing Information. EGRIFTA (tesamorelin). 2025 — 52-week continuous dosing, IGF-1 levels maintained at week-26 levels through week 52
2. Bowers CY et al. On the in vitro and in vivo activity of a new synthetic hexapeptide. Endocrinology. 1984 — GHRP/ghrelin receptor agonist mechanism
3. PNAS. Discovery of a functionally selective ghrelin receptor (GHSR1a) ligand. 2022 — β-arrestin mediated GHSR1a desensitization mechanism
4. Veldhuis JD et al. Somatostatin inhibition of GHRH-stimulated GH secretion. J Clin Endocrinol Metab — 86% GHRH pathway inhibition after exogenous GH
5. Falutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. NEJM. 2007 — Tesamorelin 26-week clinical trial efficacy

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness